Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Escherichia coli-Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer.
Goubet AG, Lordello L, Alves Costa Silva C, Peguillet I, Gazzano M, Mbogning-Fonkou MD, Thelemaque C, Lebacle C, Thibault C, Audenet F, Pignot G, Gravis G, Helissey C, Campedel L, Roupret M, Xylinas E, Ouzaid I, Dubuisson A, Mazzenga M, Flament C, Ly P, Marty V, Signolle N, Sauvat A, Sbarrato T, Filahi M, Davin C, Haddad G, Bou Khalil J, Bleriot C, Danlos FX, Dunsmore G, Mulder K, Silvin A, Raoult T, Archambaud B, Belhechmi S, Gomperts Boneca I, Cayet N, Moya-Nilges M, Mallet A, Daillere R, Rouleau E, Radulescu C, Allory Y, Fieschi J, Rouanne M, Ginhoux F, Le Teuff G, Derosa L, Marabelle A, Van Dorp J, Van Dijk N, Van Der Heijden MS, Besse B, Andre F, Merad M, Kroemer G, Scoazec JY, Zitvogel L, Loriot Y. Goubet AG, et al. Among authors: radulescu c. Cancer Discov. 2022 Oct 5;12(10):2280-2307. doi: 10.1158/2159-8290.CD-22-0201. Cancer Discov. 2022. PMID: 35929803
Assessment of diagnostic gain with hexaminolevulinate (HAL) in the setting of newly diagnosed non-muscle-invasive bladder cancer with positive results on urine cytology.
Neuzillet Y, Methorst C, Schneider M, Lebret T, Rouanne M, Radulescu C, Molinie V, Dreyfus JF, Pelcat V, Botto H. Neuzillet Y, et al. Among authors: radulescu c. Urol Oncol. 2014 Nov;32(8):1135-40. doi: 10.1016/j.urolonc.2014.04.005. Epub 2014 Jul 9. Urol Oncol. 2014. PMID: 25023786 Clinical Trial.
Re: Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications: S. A. M. Wankowicz, L. Werner, A. Orsola, J. Novak, M. Bowden, T. K. Choueiri, I. de Torres, J. Morote, G. J. Freeman, S. Signoretti and J. Bellmunt J Urol 2017;198:817-823.
Rouanne M, Lebret T, Radulescu C, Adam J. Rouanne M, et al. Among authors: radulescu c. J Urol. 2018 Mar;199(3):854-856. doi: 10.1016/j.juro.2017.09.145. Epub 2017 Nov 24. J Urol. 2018. PMID: 29179001 No abstract available.
Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results.
Neuzillet Y, Raynaud JP, Dreyfus JF, Radulescu C, Rouanne M, Schneider M, Krish S, Rouprêt M, Drouin SJ, Comperat E, Galiano M, Cathelineau X, Validire P, Molinié V, Fiet J, Giton F, Lebret T, Botto H. Neuzillet Y, et al. Among authors: radulescu c. Horm Cancer. 2019 Feb;10(1):36-44. doi: 10.1007/s12672-018-0351-8. Epub 2018 Oct 6. Horm Cancer. 2019. PMID: 30293206 Free PMC article.
128 results